Retatrutide side effects: what the published trials reported

• Most common — nausea, diarrhea, vomiting, constipation. Mostly mild-to-moderate, mostly during dose escalation.
• Notable — small, dose-dependent rise in resting heart rate, typically a few beats per minute.
• Less common but worth knowing — decreased appetite, fatigue, dyspepsia. Rare reports of pancreatitis-like events; long-term incidence still being characterized.
• Discontinuation — roughly 6 to 16% across active dose arms in Phase 2, vs. lower but non-zero on placebo.

In the Phase 2 obesity trial, gastrointestinal adverse events were the most frequently reported side effects across all active dose arms. Nausea was the most common single event, reported by approximately 35–55% of participants on the higher 8 mg and 12 mg doses, compared with roughly 13% on placebo. [1]

Most GI events were mild-to-moderate. They were concentrated in the first 12–16 weeks of treatment, during titration to maintenance dose, and largely diminished thereafter.

Across both Phase 2 trials, mean resting heart rate increased by roughly 5 to 7 beats per minute on the highest retatrutide doses, vs. essentially no change on placebo. The increase peaked around weeks 24–36 and partially attenuated thereafter. [1]

The leading hypothesis is that this is a class effect of glucagon-receptor activation, which can increase sympathetic tone. Whether it translates into meaningful cardiovascular outcomes — favorable, neutral, or unfavorable — is one of the central questions for the TRIUMPH-3 trial in patients with established cardiovascular disease.

• Hypoglycemia — uncommon when retatrutide is used alone, somewhat more common when combined with insulin or sulfonylureas in T2D trials.
• Injection-site reactions — typically mild and transient.
• Pancreatitis-like events — rare. As with the broader GLP-1 class, a small number of cases have been reported; causal attribution remains unclear.
• Gallbladder events — small numerical imbalance vs. placebo, similar to the rest of the GLP-1 class. Phase 3 will refine the magnitude.

In the Phase 2 obesity trial, treatment discontinuation due to an adverse event ranged from approximately 6% on the lowest active dose to roughly 16% on the highest dose, compared with about 4% on placebo. Most discontinuations were driven by GI events. [1]

Across published trials, the qualitative GI side-effect pattern of retatrutide closely resembles tirzepatide and semaglutide. Quantitatively, some retatrutide dose arms reported higher event rates than published comparators, but cross-trial comparisons are unreliable because of differing populations, titration schedules, and reporting conventions.

The heart-rate increase is the most distinct retatrutide-specific finding and is likely tied to its third receptor target — glucagon. Tirzepatide and semaglutide do not typically produce a heart-rate signal of comparable magnitude.

• Slow titration. The single biggest determinant of GI tolerability is dose-escalation pace. Slower escalation reduces nausea at the cost of slightly delayed weight loss.
• Smaller, less-fatty meals. GLP-1 drugs slow gastric emptying. Eating smaller portions and limiting fatty foods helps with nausea.
• Hydration and fiber. Constipation is common and modifiable through diet.
• Dose pause. If side effects are severe, clinicians often pause or step back a dose level rather than discontinue entirely.

Side-effect management is a clinical decision. This page is not medical advice. Speak to a licensed clinician about any treatment choices.